On August 12, Core Scientific, Inc. rose 5.01% in pre-market trading, trading at $20.75/share, with turnover of $113,100. The stock rebounded after closing down 7.47% at $19.44 in the prior session, with short-term oversold conditions driving technical recovery demand.

On the sector front, peer stocks IREN rose 5.65% and Riot Platforms gained 1.68% in the same session, indicating broad-based recovery across the digital infrastructure and mining space that helped attract capital inflows back to Core Scientific, Inc.

Multiple investment bank upgrades continue to provide valuation anchoring. B. Riley raised its price target to $42 from $33 while maintaining a Buy rating, and Keefe Bruyette upgraded the stock to Outperform with a $28 target. The analyst consensus mean target stands at approximately $36.71, well above current levels.

However, the company's Q2 earnings reported a net loss of $3.32 per share, far exceeding the FactSet consensus estimate of a $0.06 loss, despite revenue of $164.2 million beating expectations. Additionally, the AMD partnership announced in late July includes market-priced warrants that could dilute existing shareholders, a factor that continues to weigh on sentiment and raises questions about the sustainability of the current rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)